Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Angiotensin II Clear all
Recruiting Phase 4 Interventional

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

NCT05180773
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

A Study of LJPC-501 in Pediatric Patients With Hypotension

NCT03431077
View directory record Official record
Conditions
Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
Interventions
Angiotensin II
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Charlotte, North Carolina • Cincinnati, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Results available

N-of-1 Trials In Children With Hypertension

NCT03461003
View directory record Official record
Conditions
Pediatric Hypertension
Interventions
NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 22 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 20, 2026, 3:56 PM EDT
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Results available

Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection

NCT04340557
View directory record Official record
Conditions
SARS-CoV Infection
Interventions
Losartan
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Not applicable Interventional

Virtual Hypertension Clinic

NCT01167920
View directory record Official record
Conditions
Hypertension
Interventions
Virtual Hypertension Clinic
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

NCT04836182
View directory record Official record
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
IONIS-AGT-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Little Rock, Arkansas • Crystal River, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Results available

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

NCT02796170
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 20, 2026, 3:56 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

NCT06487585
View directory record Official record
Conditions
Vasodilatory Hypotension During or After Cardiac Surgery
Interventions
Angiotensin II
Drug
Lead sponsor
University of Maryland St. Joseph Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 20, 2026, 3:56 PM EDT
Terminated Not applicable Interventional Results available

HF Assessment With BNP in the Home: Part II

NCT02351063
View directory record Official record
Conditions
Heart Failure
Interventions
Changes of heart failure medications
Drug
Lead sponsor
Alere San Diego
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Loma Linda, California • San Diego, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Not applicable Interventional

BAROSTIM NEO Hypertension Pivotal Trial

NCT01679132
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
BAROSTIM NEO System and Medical Management
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

NCT03482440
View directory record Official record
Conditions
Preeclampsia
Interventions
Salsalate Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

NCT04936035
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, ALN-AGT01
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 3:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Left Ventricular Dysfunction, Left Atrial Dilatation, Left Ventricular Diastolic Dysfunction, Kidney Diseases, Kidney Injury, Kidney Dysfunction, Sodium Urine High, Blood Pressure Disorders, Uric Acid Retention, Angiotensin Hypertension, Autonomic Dysfunction, Autonomic Imbalance, Pediatric Kidney Disease, Pediatric Obesity, Proteinuria, Albuminuria
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
7 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 20, 2026, 3:56 PM EDT
Not listed No phase listed Observational

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

NCT04743063
View directory record Official record
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Results available

Renin and Renal Biomarker Response to Angiotensin II

NCT04558359
View directory record Official record
Conditions
Septic Shock, Acute Kidney Injury
Interventions
Standard of Care, Angiotensin II
Other · Drug
Lead sponsor
Alexander Flannery
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

NCT00527514
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine, Olmesartan medoxomil plus amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Buena Park, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 20, 2026, 3:56 PM EDT
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
View directory record Official record
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 3:56 PM EDT
Active, not recruiting Early Phase 1 Interventional

Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance

NCT07568275
View directory record Official record
Conditions
Septic Shock, Cirrhosis, Vasodilatory Shock, Acute Kidney Injury
Interventions
Giapreza
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 3:56 PM EDT
Terminated Early Phase 1 Interventional

Angiotensin 1-7 in Obesity Hypertension

NCT03604289
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Amy Arnold
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 20, 2026, 3:56 PM EDT
Terminated No phase listed Observational

Genetic Mechanisms in Human Hypertension

NCT01456208
View directory record Official record
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 20, 2026, 3:56 PM EDT
Recruiting Phase 3 Interventional

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109
View directory record Official record
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 3:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Angiotensin II Antagonism of TGF-Beta 1

NCT00320970
View directory record Official record
Conditions
Diabetic Nephropathy, Hypertension
Interventions
Candesartan
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 20, 2026, 3:56 PM EDT